比索洛尔与缬沙坦治疗顽固性高血压的临床效果比较研究

doi:10.20047/j.issn1673-7210.2023.17.15

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (666 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the clinical efficacy of Bisoprolol and Valsartan in the treatment of resistant hypertension. Methods A total of 96 patients with resistant hypertension admitted to Suzhou Hospital of Traditional Chinese Medicine in Anhui Province from June 2019 to June 2021 were selected as the research objects. They were divided into control group and experimental group by random number table method, with 48 cases in each group. The control group was treated with Valsartan, 80 mg/time, once a day on the basis of routine treatment. The experimental group was treated with Bisoprolol, 5 mg/time, once a day on the basis of routine treatment. Both groups were treated for four weeks. The clinical efficacy, and diastolic blood pressure (DBP), systolic blood pressure (SBP), inflammatory factors, lipid metabolism levels were compared between the two groups before and after treatment, and the occurrence of adverse drug reactions in the two groups was recorded. Results During the study, one case dropped out of the experimental group and two cases dropped out of the control group. There was no significant difference in clinical efficacy between the two groups (P＞0.05). After treatment, DBP and SBP of the two groups were lower than those before treatment, and the differences were statistically significant (P＜0.05). After treatment, the levels of high-sensitivity C-reactive protein, Salusin-β, and matrix metalloproteinase-3 in the two groups were lower than those before treatment, and those in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol between the two groups before and after treatment (P＞0.05). There was no significant difference in the total incidence of adverse drug reactions between the two groups (P＞0.05). Conclusion Bisoprolol and Valsartan have similar efficacy in the treatment of resistant hypertension, and they do not affect the blood lipid metabolism indexes of patients with resistant hypertension, with good safety, but Bisoprolol has more advantages in improving serum inflammatory factors in patients with resistant hypertension.

Key words： Resistant hypertension Bisoprolol Valsartan Efficacy Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Wei KANG Liming YE Ting

Cite this article:

ZHANG Wei KANG Liming YE Ting. Comparative study on the clinical effect of Bisoprolol and Valsartan in the treatment of resistant hypertension[J]. 中国医药导报, 2023, 20(17): 69-72,77.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.17.15 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I17/69

[1] Lamirault G，Artifoni M，Daniel M，et al. Resistant hypertension：novel insights [J]. Curr Hypertens Rev，2020，16（1）： 61-72.
[2] 伍勇，龚开政，杜林.顽固性高血压的诊断与治疗进展[J].医学综述，2020，26（9）：1750-1754.
[3] 苏津自.顽固性高血压是如何发展起来的？[J].中华高血压杂志，2020，28（5）：409-414.
[4] 高血压患者药物治疗管理路径编写委员会.高血压患者药物治疗管理路径专家共识[J].临床药物治疗杂志，2022，20（1）：1-24.
[5] 孙宁玲，霍勇，王继光，等.难治性高血压诊断治疗中国专家共识[J].中华高血压杂志，2013，21（4）：321-326.
[6] Momcilovic S，Jovanovic A，Radojkovic D，et al. Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension [J]. Eur J Clin Pharmacol，2020，76（11）：1539-1546.
[7] 曾位位，郭惠娟，钟国平.比索洛尔/氢氯噻嗪复合剂与缬沙坦在原发性高血压患者降压效果的比较研究[J].中国临床药理学杂志，2020，36（14）：1946-1948.
[8] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治，2019，19（1）：1-44.
[9] 高东宸.药物不良反应监察指南[M].北京：中国医药科技出版社，1996：48-51.
[10] 刘大胜，向兴华，邢云飞，等.基于文本挖掘的顽固性高血压的治疗现状及“证-药-效”的规律研究[J].世界科学技术-中医药现代化，2020，22（3）：832-838.
[11] 周芃，陈丰毅，孙运.三维标测系统射频消融去肾交感神经治疗顽固性高血压的临床疗效[J].中西医结合心脑血管病杂志，2020，18（16）：2673-2676.
[12] 杨晓东，沈师羽.西地那非联合比索洛尔治疗顽固性高血压的疗效分析[J].药物评价研究，2020，43（10）：2049- 2052.
[13] 李莉.中国高血压指南二十年[J].中国循证心血管医学杂志，2020，12（2）：129-130.
[14] 王继光.比索洛尔氨氯地平单片复方制剂治疗高血压[J].中华高血压杂志，2022，30（6）：514-516.
[15] 廖丹，田由武，陈於汝，等.比索洛尔联合奥美沙坦对老年冠心病高血压患者效果分析[J].西南国防医药，2020， 30（12）：1103-1105.
[16] 侯彩娜，代琛，王春艳，等.心舒宝胶囊联合缬沙坦治疗高血压的临床研究[J].现代药物与临床，2021，36（1）：68-71.
[17] 石薪，李广银，庞玉洪，等.高剂量缬沙坦对老年糖尿病肾病伴高血压患者血压、左心功能及血管内皮功能的影响[J].中国分子心脏病学杂志，2021，21（1）：3707-3710.
[18] 徐冬梅，龚正，丁兆生.缬沙坦分别联合氨氯地平与氢氯噻嗪治疗高血压患者的疗效比较[J].实用临床医药杂志，2022，26（10）：58-61.
[19] 王君，张静，宫航宇.沙库巴曲缬沙坦在高血压中的应用[J].中国当代医药，2021，28（6）：26-29，34.
[20] 庞翀，陈群娟.缬沙坦联合富马酸比索洛尔对老年高血压心脏病患者相关生化指标，炎症因子及氧化应激水平的影响[J].中国老年学杂志，2021，41（4）：673-676.
[21] 杨晶敏，杨文，刘洁云.螺内酯、特拉唑嗪、比索洛尔对难治性高血压患者的治疗效果及安全性研究[J].中国全科医学，2018，21（31）：3845-3849.
[22] 卫玉，张兰，汪驰，等.G蛋白β3亚单位C825T基因多态性与富马酸比索洛尔降压疗效的相关性[J].武警医学，2021，32（8）：662-666.
[23] Toyoda S，Haruyama A，Inami S，et al. Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure [J]. J Cardiol，2020，75（2）：140-147.
[24] Jackson AM，Jhund PS，Anand IS，et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction [J]. Eur Heart J，2021，42（36）：3741-3752.
[25] Tocci G. Antihypertensive efficacy of LCZ696（sacubitril/ valsartan）in hypertension [J]. Cardiology，2020，145（9）： 599-600.
[26] 李运革，庹田.依那普利联合缬沙坦治疗高血压合并冠心病的临床研究[J].中西医结合心脑血管病杂志，2020，18（12）：1950-1953.